UnionStrong (Beijing) Technology Co., Ltd. - 强联智创（北京）科技股份有限公司

UnionStrong (Beijing) Technology Co., Ltd., known by its brand UnionStrong, is a Beijing-based medical AI and surgical robotics company founded in September 2016 and headquartered in the Beijing Economic-Technological Development Area (Yizhuang). The company focuses on AI-driven, full-cycle solutions for cerebrovascular disease, spanning diagnosis, surgical treatment planning, robotic-assisted intervention, and post-operative follow-up, with intracranial aneurysm treatment as its primary clinical focus.

The company's flagship UKnow product family combines AI-based surgical planning software with a miniaturized surgical robot for neuro-interventional procedures. In October 2022, a UKnow-branded product received China's first NMPA Class III innovative medical device certification for an AI-plus-treatment device, described by the company as pioneering AI-assisted surgical treatment in the country. UnionStrong has continued to iterate the hardware, and by early 2025 was preparing a fourth-generation miniaturized surgical robot compressed to roughly the size of a desktop printer, intended to make robotic-assisted aneurysm treatment more accessible to grassroots hospitals. Alongside the robotic platform, the company offers the UGuard imaging-analysis software for AI-assisted diagnosis of cerebrovascular conditions, as well as the UAlpha risk-assessment tools and the UData multimodal data-management system supporting its broader diagnostic and treatment ecosystem.

UnionStrong has raised multiple financing rounds, progressing through a Series C round and subsequent Series D and D-plus rounds, with a Series D round of nearly RMB 100 million reported around December 2023 backed by investors including a Yantai biomedical industry fund. As of early 2025 the company reported quarterly output value approaching RMB 100 million, roughly double the prior year, and cumulative treatment of close to ten thousand patients using its technology, with plans to obtain additional Class III device registrations domestically and pursue overseas regulatory approval.

Operating from its Beijing headquarters, UnionStrong positions itself at the intersection of AI software and robotic hardware for neurovascular intervention, targeting hospital neurosurgery and neuro-interventional departments across China as its core customer base.